Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-02T22:06:29.598Z Has data issue: false hasContentIssue false

Evaluation of enzyme immunoassay (EIA) as a screening method for hepatitis B markers in an open population

Published online by Cambridge University Press:  15 May 2009

J. A. McCready
Affiliation:
Hepatitis Branch, Division of Viral and Rickettsial Diseases, Center for Infectious Disease, Centers for Disease Control, Public Health Service, U.S. Department of Health and Human Services, World Health Organization Collaborating Center for Reference and Research cm Viral Hepatitis, Atlanta, Georgia30333
D. Morens
Affiliation:
Department of Public Health Sciences, University of Hawaii School of Public Health, Honolulu, Hawaii 96822
H. A. Fields
Affiliation:
Hepatitis Branch, Division of Viral and Rickettsial Diseases, Center for Infectious Disease, Centers for Disease Control, Public Health Service, U.S. Department of Health and Human Services, World Health Organization Collaborating Center for Reference and Research cm Viral Hepatitis, Atlanta, Georgia30333
P. J. Coleman
Affiliation:
Hepatitis Branch, Division of Viral and Rickettsial Diseases, Center for Infectious Disease, Centers for Disease Control, Public Health Service, U.S. Department of Health and Human Services, World Health Organization Collaborating Center for Reference and Research cm Viral Hepatitis, Atlanta, Georgia30333
M. Kane
Affiliation:
Hepatitis Branch, Division of Viral and Rickettsial Diseases, Center for Infectious Disease, Centers for Disease Control, Public Health Service, U.S. Department of Health and Human Services, World Health Organization Collaborating Center for Reference and Research cm Viral Hepatitis, Atlanta, Georgia30333
G. Schatz
Affiliation:
Hepatitis Branch, Division of Viral and Rickettsial Diseases, Center for Infectious Disease, Centers for Disease Control, Public Health Service, U.S. Department of Health and Human Services, World Health Organization Collaborating Center for Reference and Research cm Viral Hepatitis, Atlanta, Georgia30333
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Commercially available kits for detection of hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) by enzyme immunoassay (EIA) were evaluated in American Samoa during a public health programme to eliminate the transmission of hepatitis B. The first 19184 serum specimens obtained, representing 68% of the total cooperating population, were initially tested for anti-HBs, and those without detectable antibody were tested for HBsAg. All the antigen-positive serum samples, and a selection of the antigen-and antibody-negative specimens were tested by radioimmunoassay (RIA) for detection of both markers. Compared with the standard tests, the EIA kits for anti-HBs and HBsAg performed well; sensitivity and specificity were 90·3 and 96·0%, respectively, for antibody, and 97·8 and 97·9% respectively for antigen. Substantial disagreement between the EIA and RIA tests for HBsAg was found only for specimens considered weakly reactive by EIA. Few differences were found between three EIA method options for follow-up HBsAg testing of weakly reactive serum specimens; each option contributed about equally to improved test specificity for these ‘borderline’ specimens. Based on their demonstrated equivalence to the standard RIA tests, we conclude that the EIA kits for anti-HBs and HBsAg detection are suitable for use in hepatitis B control programmes in open populations.

Type
Research Article
Copyright
Copyright © Cambridge University Press 1991

References

REFERENCES

1.Nomura, A, Stemmermann, GN, Wasnich, RD. Presence of hepatitis B surface antigen before primary hepatocellular carcinoma. JAMA 1982; 247: 2247–9.CrossRefGoogle ScholarPubMed
2.Beasley, RP, Hwang, L, Lin, C, Chien, C. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22.707 men in Taiwan. Lancet 1981; ii: 1129–33.CrossRefGoogle Scholar
3.Alward, WLM, McMahon, BJ, Hall, DB, Heywood, WL, Francis, DP, Bender, TR. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J. Inf Dis 1985; 151: 604–9.CrossRefGoogle ScholarPubMed
4.World Health Organization. Prevention of hepatocellular carcinoma by immunization. Bull WHO 1983; 61: 731–44.Google Scholar
5.Wolters, G, Kuijepers, L, Schuurs, A. Solid-phase enzyme-immunoassay or detection of hepatitis B surface antigen. J Clin Pathol 1976; 29: 873–9.CrossRefGoogle ScholarPubMed
6.Caldwell, W, Barrett, JT. Enzyme immunoassay for hepatitis B and its comparison to other methods. Clin Chim Acta 1977; 81: 305–9.CrossRefGoogle ScholarPubMed
7.Wei, R, Knight, CJ, Zimmerman, DH, Bond, HE. Solid-phase enzyme immunoassay for hepatitis B surface antigen. Clin Chem 1977; 23: 813–15.CrossRefGoogle ScholarPubMed
8.Mancal, P, Benda, R, Koenig, J, Helm, R, Nemecek, V, Kyselova, M. Sensitivity and specificity of Czechoslovak ELISA HBsAg sevac tests: comparison with other third-generation tests and counter-immunoelectrophoresis. J Hyg Epidemiol Microbial Immunol 1983; 27: 425–35.Google ScholarPubMed
9.Aaij, C, Winkel, JN. Comparison of the enzyme-linked immunosorbent assay and the radio-immunoassay methods in a serological laboratory. In: Malvano, R. ed. Immunoenzymatic assay techniques. The Hague: Martinus Nijhoff. 1980; 184–96.Google Scholar
10.Kang, LY. Epidemiology and prevention of viral hepatitis in China. Shanghai international symposium on liver cancer and hepatitis. Shanghai: 1986: 230–59.Google Scholar
11.Heijtink, RA, Kruining, J, Schalm, SW, Masurel, N. Comparison of two techniques for detecting antibody to HBsAg during a hepatitis B vaccine study. J Virol Methods 1985; 10: 333–9.CrossRefGoogle ScholarPubMed
12.Bureau of the Census. 1980 Census of population, American Samoa. Washington: U.S. Dept. of Commerce, 1982; PC80–1-A56:1.Google Scholar